Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer vaccine
Biotech
ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial
IO Biotech's cancer vaccine, in combination with Keytruda, delivered an objective response rate of 44.4%, hitting the study's primary endpoint.
Darren Incorvaia
Sep 14, 2024 2:30am
Ultimovacs cancer vaccine fails again, enters last chance saloon
Aug 6, 2024 4:14am
BioNTech, Regeneron rack up response rate win for cancer vaccine
Jul 30, 2024 6:45am
ASCO: It's back to the basics for cancer drug developers
Jun 5, 2024 10:55am
Merck's 3-pronged cancer plan stars Moderna-partnered vaccine
Jun 3, 2024 8:00am
mRNA vaccine for glioblastoma targets tumors in humans and dogs
May 7, 2024 5:30am